Form 8-K - Current report:
SEC Accession No. 0001193125-25-035162
Filing Date
2025-02-25
Accepted
2025-02-25 16:18:22
Documents
13
Period of Report
2025-02-19
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d926019d8k.htm   iXBRL 8-K 21431
  Complete submission text file 0001193125-25-035162.txt   138891

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA allo-20250219.xsd EX-101.SCH 2841
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE allo-20250219_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE allo-20250219_pre.xml EX-101.PRE 10806
15 EXTRACTED XBRL INSTANCE DOCUMENT d926019d8k_htm.xml XML 3518
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 25663516
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)